glp-1 obesity drug news october 9 2025 Novo, Lilly weight-loss drugs should be first option treatments, European doctors say Half of people stop taking
Description
There are several reasons to explain this limited beneficial effect on HbA1c (and also on body weight)
At the same time, new therapeutic approaches are emerging
They reduce inflammation in the kidneys They may improve blood flow in the kidney's tiny filters They help lower blood pressure Weight loss and better blood sugar control indirectly benefit the kidneys What Do Scientific Studies Tell Us
What is CagriSema and How Does It Work
The duration of trials ranged from 6 to 26 weeks
Stay informed about dual agonists, oral formulations and combination therapies. Why data matters and how to get ahead Real-world evidence is essential for guiding coverage decisions, tailoring treatment protocols and maximizing patient outcomes
